Thera-SAbDab

ZENOCUTUZUMAB

> Structural Summary

Therapeutic	Zenocutuzumab
Target 1	ERBB3
Heavy Chain 1	QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDHGSRHFWSYWGFDYWGQGTLVTVSS
Light Chain 1	DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK
100% seqID Fv 1 Structure	5o4o [Fvs: BA], 5o7p [Fvs: BA]
99% seqID Fv 1 Structure	None
95-98% seqID Fv 1 Structure	None
Target 2	ERBB2
Heavy Chain 2	QVQLVQSGAEVKKPGASVKLSCKASGYTFTAYYINWVRQAPGQGLEWIGRIYPGSGYTSYAQKFQGRATLTADESTSTAYMELSSLRSEDTAVYFCARPPVYYDSAWFAYWGQGTLVTVSS
Light Chain 2	DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPTFGQGTKVEIK
100% seqID Fv 2 Structure	5o4g [Fvs: BA]
99% seqID Fv 2 Structure	None
95-98% seqID Fv 2 Structure	None

100% seqID Structure [Fv 1]	5o4o [Fvs: BA]
100% seqID Structure [Fv 1]	5o7p [Fvs: BA]
100% seqID Structure [Fv 2]	5o4g [Fvs: BA]

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder: [Fv 1] [Fv 2]
Test for possible therapeutic developability issues with TAP: [Fv 1] [Fv 2]
Assign canonical forms by sequence with SCALOP: [Fv 1] [Fv 2]
Number the sequences in any numbering scheme with ANARCI: [Fv 1 H] [Fv 1 L] [Fv 2 H] [Fv 2 L]

Format	Bispecific mAb
Isotype	G1
Highest Clinical Trial (Jan '20)	Phase-II
Estimated Status (Jan '20)	Active
Recorded Developmental Technology	GlymaxX Technology
INN Year Proposed	2017
INN Year Recommended	2018
Companies Involved	Merus
Conditions Approved	na
Conditions Active	Breast cancer, Colorectal cancer, Gastric cancer, Non-small cell lung cancer
Conditions Discontinued	Endometrial cancer, Ovarian cancer
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]